Cohen & Steers

Recent news

• Company notice
  CNS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Charles Faith L.
  SEC · 2026/5/20
• Company notice
  INSILICO: VOLUNTARY ANNOUNCEMENTINSILICO MEDICINE AND TENACIA BIOTECHNOLOGY EXPANDAI-DRIVEN CNS COLLABORATION WITH ADDITIONAL DEAL VALUEUP TO USD94.75 MILLION
  HKEX · 2026/3/26
• Rating change
  Evercore Initiates Cohen & Steers(CNS.US) With Buy Rating, Announces Target Price $75
  Market Newswire · 2026/4/10
• Rating change
  Maxim Group Maintains CNS Pharmaceuticals(CNSP.US) With Buy Rating, Maintains Target Price $20
  Market Newswire · 2025/11/20
• Evercore Maintains Cohen & Steers(CNS.US) With Buy Rating, Raises Target Price to $84
  Market Newswire · 2026/7/10
• Rating change
  BofA Securities Maintains Cohen & Steers(CNS.US) With Sell Rating, Maintains Target Price $53
  Market Newswire · 2026/4/6
• Company notice
  CNS: We have launched "U-Way Recovery Solutions," a service that supports business continuity and rapid recovery in OCI environments.
  JPX · 2026/9/16
• Rating change
  Maxim Group Maintains CNS Pharmaceuticals(CNSP.US) With Buy Rating, Cuts Target Price to $10
  Market Newswire · 2026/3/6
• CN U.S. Rail Subsidiaries And Amtrak Announce Agreements To Strengthen Partnership And Support Safe, Reliable Passenger And Freight Service On CN's U.S. Rail Network
  Benzinga · 2026/9/17
• Rating change
  Evercore Maintains Cohen & Steers(CNS.US) With Buy Rating, Raises Target Price to $82
  Market Newswire · 2026/6/8
• LG CNS Targets U.S. Ad Market With Agentic AI-Powered Marketing Solution
  PR Newswire · 2026/8/31
• LG CNS to Acquire KRW381.4 Billion in NVIDIA GPU Equipment for AI Factory
  MT Newswires · 2026/9/11
• Company notice
  LG CNS Co: Report on Significant Holdings of Stocks, Etc. (Short Form)
  OPENDART · 2026/10/2
• Company notice
  CNS: An IR interview article has been published (IR Agents).
  JPX · 2026/6/5
• Rating change
  Fosun Pharma (600196) Commentary: Steadily advancing in the fields of metabolism, CNS, and oncology; continuous progress in innovation and transformation.
  Tianfeng Securities · 2026/1/28
• Evercore Maintains Cohen & Steers(CNS.US) With Buy Rating, Raises Target Price to $88
  Market Newswire · 2026/8/10
• Rating change
  Evercore Maintains Cohen & Steers(CNS.US) With Buy Rating, Cuts Target Price to $74
  Market Newswire · 2025/10/9
• Rating change
  Evercore Maintains Cohen & Steers(CNS.US) With Buy Rating, Maintains Target Price $77
  Market Newswire · 2025/11/7
• Rating change
  Maxim Group Maintains CNS Pharmaceuticals(CNSP.US) With Buy Rating, Maintains Target Price $10
  Market Newswire · 2026/5/15
• Rating change
  Evercore Maintains Cohen & Steers(CNS.US) With Buy Rating, Cuts Target Price to $76
  Market Newswire · 2026/4/20

Headlines are aggregated automatically and are not independently verified or edited by our team.